The First Department of Gynecological Oncology, Linyi Cancer Hospital, Linyi, 276002, China.
Liangzhu Laboratory, Zhejiang University, Hangzhou, 311121, China.
J Hematol Oncol. 2024 Nov 28;17(1):116. doi: 10.1186/s13045-024-01635-5.
CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual roles in phagocytosis and immune modulation. Here we show the clinical results of CAR-macrophage treatment of two ovarian cancer patients. The CAR-macrophages were produced by introducing a mesothelin targeting CAR to patients' primary peripheral blood mononuclear cell-derived macrophages, and the products were infused to patients intravenously. Our data show good safety of the infusion product, and the efficacy can be further improved. Intraperitoneal infusion of CAR-macrophages has proven effective in treating intraperitoneal tumors in a preclinical model, paving the way for demonstrating proof-of-concept clinical efficacy of CAR-macrophages in the treatment of intraperitoneal tumors.
嵌合抗原受体修饰的巨噬细胞在治疗实体瘤方面具有广阔的前景，因为其能够高度浸润肿瘤，并在吞噬作用和免疫调节方面发挥双重作用。在此，我们报告了嵌合抗原受体修饰的巨噬细胞治疗两名卵巢癌患者的临床结果。通过将一种针对间皮素的嵌合抗原受体导入患者的原代外周血单个核细胞来源的巨噬细胞中，制备了嵌合抗原受体修饰的巨噬细胞，然后将产物静脉输注给患者。我们的数据表明输注产品具有良好的安全性，并且疗效可以进一步提高。嵌合抗原受体修饰的巨噬细胞腹腔内输注已在临床前模型中被证明对腹腔内肿瘤有效，为证明嵌合抗原受体修饰的巨噬细胞在治疗腹腔内肿瘤方面的临床疗效提供了概念验证。
